Attached files
| file | filename |
|---|---|
| EX-99.1 - RADIENT PHARMACEUTICALS Corp | v224066_99-1.htm |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
Date of Report (Date of Earliest Event Reported): May 24, 2011
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-16695
|
33-0413161
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039
(Address of principal executive offices (zip code))
714-505-4461
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
Section 2- Financial Information
Item 2.02-Results of Operations and Financial Condition
Section 7 – Regulation FD
Item 7.01 – Regulation FD Disclosure
On today’s date, we issued a press release stating that we intend to file our Annual Report on Form 10-K for the year ended December 31, 2010 after market today and anticipate filing our Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 on or before the close of business on Tuesday, June 7, 2011. The press release also included preliminary financial results we expect to report in our Form 10—Q.
A copy of the press release is attached hereto as Exhibit 99.1.
Section 9 – Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits
(c) Exhibits
| Exhibit No. | Description |
|
99.1
|
Press Release
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 24, 2011
|
RADIENT PHARMACEUTICALS CORPORATION
|
||
|
/s/ Douglas MacLellan
|
||
|
Name: Douglas MacLellan
Title: Chief Executive Officer |
||